Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary
(firmenpresse) - LAS VEGAS, NV -- (Marketwired) -- 12/18/14 -- Cell MedX Corp. (OTCBB: CMXC) (the "Company") is pleased to announce the formation of its wholly owned subsidiary, Avyonce Cosmedics Inc. ("Avyonce"). Avyonce will concentrate its efforts on the resale and marketing of spa technology and equipment to the worldwide beauty and wellness industry. Avyonce has received its first order for approximately US$55,000 from Dubai, United Arab Emirates.
Cell MedX Corp. is an early development stage company focused on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes by developing technologies to help manage the illness and related complications. Through its wholly owned subsidiary, Avyonce Cosmedics Inc., Cell MedX Corp. is also engaged in the resale and marketing of spa technology and equipment.
On behalf of the Board of Directors of Cell MedX Corp.
Frank McEnulty
Chief Executive Officer and President.
Forward Looking Statements
This press release contains forward-looking statements. Forward-looking statements are subject to risks, uncertainties and assumptions and are identified by words such as "expects," "intends," "estimates," "projects," "anticipates," "believes," "could," and other similar words. All statements addressing product performance, events, or developments that the Company expects or anticipates, as well as sales to its customers, will occur in the future are forward-looking statements. Because the statements are forward-looking, they should be evaluated in light of important risk factors and uncertainties, some of which are described in the Company's Quarterly, Annual and Current Reports filed with the United States Securities and Exchange Commission (the "SEC"). Should one or more of these risks or uncertainties materialize, or should any of the Company's underlying assumptions prove correct, actual results may vary materially from those currently anticipated. In addition, undue reliance should not be placed on Company's forward-looking statements. In particular, the Company's e-balance Technology is still in development. The Company does not currently have any commercially marketable products based on the e-balance Technology, and there is no assurance that the Company will be successful in its development efforts. Except as required by law, Cell MedX Corp. disclaims any obligation to update or publicly announce any revisions to any of the forward-looking statements contained in this press release. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. No stock exchange, securities commission or other regulatory body has reviewed nor accepts responsibility for the adequacy or accuracy of this release. Investors are advised to carefully review the reports and documents that Cell MedX Corp. files from time to time with the SEC, including its Annual, Quarterly and Current Reports.
For further information about Cell MedX Corp. please visit the Company's website at . Or phone us at 310-230-2300 x-1.
Cell MedX Corp.
310-230-2300 x-1
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 18.12.2014 - 13:00 Uhr
Sprache: Deutsch
News-ID 360426
Anzahl Zeichen: 0
contact information:
Town:
LAS VEGAS, NV
Kategorie:
Family
Diese Pressemitteilung wurde bisher 249 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Cell MedX Corp. (CMXC) Announces the First Order Received by Its Newly Formed Wholly Owned Subsidiary"
steht unter der journalistisch-redaktionellen Verantwortung von
Cell MedX Corp. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
